The flu vaccine window is open: what U.S. families should schedule this week (2026)

September is the month to turn a flu-vaccine plan into an appointment. CDC surveillance remains quiet, but the 2026–27 vaccine guidance is current, and one new U.S. study found that many people who intended to vaccinate never completed the appointment. For the week of August 31 through September 7, the practical move is to check records and book care rather than wait for a new effectiveness estimate or another product announcement.

Flu activity is low, but the calendar is open

CDC published and updated FluView Week 34 on September 4. The report covers the week ending August 29. Clinical laboratories found influenza in 300 of 27,424 tested specimens, or 1.1%. Public-health laboratories found 17 positive specimens: 15 influenza A and two influenza B. No H5 specimens and no new confirmed human infection with a novel influenza virus were reported. 1

The other measures were also low. Influenza-like illness accounted for 1.3% of visits nationwide. Fifty-five jurisdictions reported minimal activity, and none reported low, moderate, high, or very high activity. FluSurv-NET had recorded 31,005 laboratory-confirmed influenza-associated hospitalizations from October 1, 2025 through August 29, 2026; the Week 34 hospitalization rate was 0.1 per 100,000 people. 1

Low activity gives families time to schedule. It does not provide a 2026–27 vaccine-effectiveness percentage. CDC's vaccination-trends page, updated September 4, still presents flu data through May 23, 2026, and says updates for the 2025–26 season ended May 29. The page contains no 2026–27 effectiveness estimate. 2

What CDC says to schedule now

CDC's seasonal flu guidance was updated September 1 for the 2026–27 season. All U.S. flu vaccines for this season are trivalent, meaning they target two influenza A viruses and one influenza B/Victoria virus. For most people who need one dose, September and October are good times to vaccinate, with vaccination ideally completed by the end of October. Antibody protection takes about two weeks to develop. 3

Children need an early records check. Some children need two flu doses, with the second dose at least four weeks after the first. CDC says the first dose should be given as soon as vaccine is available for a child who needs two doses. 3

Adults 65 and older have three preferentially recommended options when available: Fluzone High-Dose, Flublok Recombinant, and Fluad Adjuvanted. A different age-appropriate flu vaccine remains an option when those products are unavailable. People younger than 65 do not have one CDC-preferred licensed flu product, apart from specific medical circumstances such as certain transplant treatment. 3

The practical choice is therefore simple: ask which age-appropriate vaccine is available, ask whether a child needs two doses, and use the person's age and medical history to discuss the product. Waiting for a 2026–27 effectiveness estimate would leave the appointment unscheduled while the current CDC guidance already supports fall vaccination.

Measles makes record checks more urgent

CDC updated its measles page on September 4 with data through September 3 at noon. The page lists 3,134 confirmed U.S. measles cases in 2026, 38 outbreaks, and 248 hospitalizations, or 8% of cases. Ninety-five percent of cases, 2,969 of 3,134, were associated with an outbreak. 4

Vaccination records remain the household task. CDC lists 94% of 2026 cases as unvaccinated or having an unknown vaccination status, 3% after one MMR dose, and 3% after two doses. A parent or caregiver who cannot find a record should ask a clinician or local health department how to document prior vaccination and whether another dose fits the person's age and circumstances. 4

The measles update does not change the flu schedule. It changes what belongs in the same records check: MMR doses, flu history, COVID-19 dose dates, allergies, pregnancy, and conditions that raise the risk of severe respiratory illness.

The product pipeline is quiet this week

Moderna's current mFLUSIVA post is dated August 5. The post says the FDA approved mFLUSIVA for adults age 50 and older. For adults 65 and older, the approval relied on evidence that the vaccine produced an immune response, while additional research continues to confirm clinical benefit. Moderna expects U.S. availability for eligible adults during the 2026–27 respiratory-virus season. 5

That status gives adults 50 and older a product to ask about when local supply and personal history make the question relevant. The post does not provide a local inventory list, a price, or a coverage decision. A pharmacy or clinician must answer those practical questions.

Pfizer's checked COVID-19 update archive lists August 27 as its newest entry; the archive contains no respiratory-vaccine entry dated August 31 through September 7. The most recent entry remains the XFG-adapted COMIRNATY approval for adults 65 and older and people ages 5 through 64 with at least one condition that raises the risk of severe COVID-19. 6 7

For families, the pipeline message is steady: local access may change as products arrive, but this week's checked sources add no new reason to postpone an age-appropriate flu appointment while waiting for another formulation.

What the new research changes, and what it leaves alone

A paper published online August 31 in Nature Immunology examined how immune memory forms in the lungs after influenza infection. In mice, a memory-stage monocyte population persisted for more than four months. Removing those cells reduced the formation of lung CD8 T cells that can respond quickly to later exposure. Giving galectin-1 with an intranasal influenza vaccine produced stronger memory CD8 T-cell responses in the mouse model. The abstract gives no human cohort and no mouse count, so the result is preclinical vaccine-design research rather than a household dosing study. 8

A separate study published September 6 in Vaccine followed 3,390 U.S. adults across the 2025–26 respiratory-virus season. In August 2025, 73% said they were willing to get a flu vaccine. By March 2026, 17% of the willing group remained unvaccinated for flu. Participants most often pointed to difficulty finding a convenient time, place, or appointment; the researchers also found that a missing prior-season vaccination was strongly associated with later nonvaccination. 9

The study did not test a vaccine product or set a new dosing schedule. It points to a fix families can use immediately: turn the intention into a scheduled visit before the fall calendar fills up.

The household checklist

For every family member: Find the MMR record, flu history, COVID-19 dose dates, allergies, pregnancy status, and conditions that affect respiratory-virus risk. Ask a clinician or local health department to resolve a missing record.
For a child who may need two flu doses: Ask whether two doses are needed and schedule the second dose at least four weeks after the first. Start as soon as vaccine is available.
For most people who need one flu dose: Book vaccination for September or October, aiming to finish by the end of October. Ask which age-appropriate trivalent vaccine is available.
For an adult age 65 or older: Ask whether Fluzone High-Dose, Flublok Recombinant, or Fluad Adjuvanted is available. Use another age-appropriate vaccine if a preferred product is unavailable.
For an adult age 50 or older asking about mFLUSIVA: Ask whether the product is stocked locally, whether the person's age and medical history fit the approval, and how insurance or out-of-pocket cost will work.
For someone considering the 2026–27 COVID-19 vaccine: Bring prior dose dates, infection history, allergies, age, and underlying conditions to the vaccinating clinician. The current Pfizer approval boundary covers adults 65 and older and people ages 5 through 64 with at least one qualifying condition.

This article provides general health information for U.S. families. A clinician, pharmacist, or local health department can apply current recommendations to an individual record.